Dr. Amy Barone is a pediatric oncologist who joined the US Food and Drug Administration (FDA) in January 2014 as a medical officer for the CNS, Pediatric Solid Tumors, and Rare Cancers.
As a medical officer, she is responsible for the review and regulatory oversight of expanded access programs, numerous investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and single patient INDs.
She is very involved in the FDA effort to move the field of oncology drug development for rare diseases forward.